- In early September 2026, Wall Street analysts projected that The Cooper Companies would report quarterly earnings of US$1.11 per share on about US$1.10 billion in revenue, implying modest year-over-year growth and stronger contributions from its CooperVision and CooperSurgical businesses.
- An interesting angle in these forecasts is the expected lift from fertility and office & surgical categories, suggesting that investors are paying attention not just to headline numbers but also to how specific growth areas could reshape the company’s revenue mix.
- Now we’ll examine how these upbeat earnings and segment growth expectations might influence Cooper Companies’ existing investment narrative and risk profile.
This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
Cooper Companies Investment Narrative Recap
To own Cooper Companies, you generally need to believe in a steady shift toward premium contact lenses and a recovery in women’s health and fertility. The latest analyst forecasts for modestly higher earnings and revenue do not materially alter that story in the near term, but they do put short term focus on whether CooperVision’s product mix and CooperSurgical’s fertility and office & surgical demand can grow fast enough to offset pricing pressure and uneven procedure volumes.
Against this backdrop, the company’s plan to report Q3 2026 results on September 9 sits at the center of the current catalyst. That earnings release will show how close actual numbers come to the projected US$1.11 in EPS on US$1.10 billion in revenue, and how much of that reflects traction in CooperVision and CooperSurgical rather than one off factors, which matters a lot for investors tracking both the MyDAY rollout and the fertility recovery story.
Yet beneath these encouraging forecasts, investors should be aware of ongoing pressure from contact lens pricing and uneven fertility demand that could still...
Read the full narrative on Cooper Companies (it's free!)
Cooper Companies' narrative projects $4.9 billion revenue and $817.1 million earnings by 2029. This requires 5.1% yearly revenue growth and a roughly $581 million earnings increase from $235.8 million today.
Uncover how Cooper Companies' forecasts yield a $80.57 fair value, a 14% upside to its current price.
Exploring Other Perspectives
Compared with consensus, the most pessimistic analysts assume earnings of about US$841.2 million by 2029 on US$4.9 billion in revenue and see risks like uneven fertility demand as more limiting, which shows you how widely opinions can differ and why this latest earnings news could cause both narratives to shift.
Explore 5 other fair value estimates on Cooper Companies - why the stock might be worth 38% less than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Cooper Companies research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Cooper Companies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cooper Companies' overall financial health at a glance.
Interested In Other Possibilities?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com